Growth hormone treatment in prepubertal children with celiac disease and growth hormone deficiency.

What Was Tested

This controlled clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of celiac disease and gluten sensitivity.

Who Took Part

The abstract describes 14 children taking part.

The age groups tagged for this paper are young children and children, both men and women.

A total of 14 prepubertal children affected by CD and GHD with no catch-up growth after >/=12 months of gluten-free diet and a reversion to seronegativity for antiendomysium antibodies and 10 age-matched prepubertal children with idiopathic GHD (IGHD) entered the study.

Height, growth rate, and body mass index were measured at the time of diagnosis of CD, at the time of endocrinological evaluation, and after the first, second, and third year of GH replacement therapy.

What Was Measured

The subject headings attached to it are Body Height, Body Mass Index, Celiac Disease, Child Development, Growth Disorders and Human Growth Hormone.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 14 children in people with celiac disease and gluten sensitivity.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (Journal of pediatric gastroenterology and nutrition), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Celiac disease and gluten sensitivity research.